Transitioning from minimal immune-activated TAM phenotype leads to enhanced phagocytosis levels in tumor-associated microglia (49), which results in increased immune responses and improved checkpoint blockade targeting PD-1/PD-L1 (52). The gene discussed is CD274; the disease is neoplasm.